Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 512 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Genotyping Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Personalized Dietary Program and Markers of Wellness

NCT03424395
View directory record Official record
Conditions
Healthy, Metabolism
Interventions
Personalized dietary and wellness program
Other
Lead sponsor
Habit, LLC
Industry
Eligibility
30 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

NCT01858766
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
50
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

NCT01581138
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
VX-222, telaprevir, ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Anaheim, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Not applicable Interventional Results available

Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery

NCT03534063
View directory record Official record
Conditions
Pain, Postoperative
Interventions
CYP2D6-guided opioid therapy
Genetic
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gainesville, Florida • Summerfield, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

NCT01058512
View directory record Official record
Conditions
Hepatitis C
Interventions
NOV-205
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

NCT03069365
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
La Jolla, California • Pasadena, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

NCT01290679
View directory record Official record
Conditions
Hepatitis C
Interventions
Placebo, TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Not applicable Interventional

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

NCT00000859
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
32
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 26, 2026, 2:08 PM EDT
Recruiting No phase listed Observational

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

NCT01145196
View directory record Official record
Conditions
Genotype, Retinal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Completed No phase listed Observational

A Comparison of Two Anti-HIV Treatment Plans

NCT00005915
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
21
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

NCT01132313
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127, BI 201335, Ribavirin, BI 207217
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMD

NCT02834650
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Cardiac MRI with contrast, Cardiac MRI without contrast, Blood Test, Heart Rate, Pulmonary Function Test, Genetic Testing, Repeat MRI scan
Other
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 21 Years · Male only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Orange, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 26, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers

NCT00001284
View directory record Official record
Conditions
Genotype, Allelic Frequencies of Genetic Markers, Brain Mapping, Brain Disease, fMRI
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
2,802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 26, 2026, 2:08 PM EDT
Completed No phase listed Observational

Pharmacogenomics Analysis of Morphine Pharmacokinetics in Pediatric Tonsillectomy and Adenoidectomy

NCT00836264
View directory record Official record
Conditions
Tonsillectomy, Adenoidectomy, Pharmacokinetics
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 18 Years
Enrollment
878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 26, 2026, 2:08 PM EDT
Withdrawn Early Phase 1 Interventional

CYP2C19 Genotype Predictor of Gastric Acid Suppression

NCT01824199
View directory record Official record
Conditions
Esophagitis
Interventions
Omeprazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body

NCT00029341
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment Interruption
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT02167945
View directory record Official record
Conditions
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
Interventions
ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
48
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

NCT01728324
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
31
States / cities
North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 26, 2026, 2:08 PM EDT
Recruiting Not applicable Interventional

An Evaluation of the Impact of Pharmacist Comprehensive Medication Management With Pharmacogenomic Results to Improve Depression Outcomes in Community Pharmacies.

NCT07373470
View directory record Official record
Conditions
Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services
Interventions
Comprehensive medication management with PGx testing results, Usual Care
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

NCT01984294
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, RBV, GS-9669
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 26, 2026, 2:08 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Phenotype, Genotype and Biomarkers 2

NCT04875416
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
7 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
3
States / cities
Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Active, not recruiting No phase listed Observational

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

NCT02279004
View directory record Official record
Conditions
NSCLC, Melanoma
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection

NCT02253550
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Peter J. Ruane, M.D.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 26, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Tolcapone for Cognition in Schizophrenia

NCT00044083
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Tolcapone
Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 26, 2026, 2:08 PM EDT